These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29206234)

  • 1. Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    Jędroszka D; Orzechowska M; Hamouz R; Górniak K; Bednarek AK
    PLoS One; 2017; 12(12):e0188842. PubMed ID: 29206234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
    Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
    PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy.
    Jiang G; Hu Q; Wang H; Ding W; Zhang N; Wu Y; Zhou Q; Sun C; Xia G; Ding Q; Na R; Xu K
    Ann Clin Lab Sci; 2018 Jan; 48(1):18-28. PubMed ID: 29530992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
    Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
    Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
    Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
    Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
    BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.
    Whiteland H; Spencer-Harty S; Thomas DH; Davies C; Morgan C; Kynaston H; Bose P; Fenn N; Lewis PD; Bodger O; Jenkins S; Doak SH
    Exp Mol Pathol; 2013 Oct; 95(2):220-6. PubMed ID: 23933194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamin A/C might be involved in the EMT signalling pathway.
    Zuo L; Zhao H; Yang R; Wang L; Ma H; Xu X; Zhou P; Kong L
    Gene; 2018 Jul; 663():51-64. PubMed ID: 29665450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
    Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
    Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
    Johnston WL; Catton CN; Swallow CJ
    BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma.
    Lai CY; Chen CM; Hsu WH; Hsieh YH; Liu CJ
    Int J Med Sci; 2017; 14(12):1263-1267. PubMed ID: 29104483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
    Pistore C; Giannoni E; Colangelo T; Rizzo F; Magnani E; Muccillo L; Giurato G; Mancini M; Rizzo S; Riccardi M; Sahnane N; Del Vescovo V; Kishore K; Mandruzzato M; Macchi F; Pelizzola M; Denti MA; Furlan D; Weisz A; Colantuoni V; Chiarugi P; Bonapace IM
    Oncogene; 2017 Oct; 36(40):5551-5566. PubMed ID: 28581528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
    Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
    Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.